Marco Meglio

GA Depot, which remains under review by the FDA, showed a safe and tolerable profile in an additional 52-week extension period.

These data, presented at 2024 ACTRIMS Forum, highlight the impacts neurofilament light has on patients with multiple sclerosis irrespective of race or ethnicity.

The conversations behind cerebroprotection in stroke have begun to get louder, with a pipeline that includes several different approaches to treatment.

ATH-1105 protected various cell culture systems from glutamate-mediated toxicity and its pathological alterations, which include mitochondrial dysfunction, apoptotic signaling, and TDP-43 mis-localization, among others.

The antisense oligonucleotide will continue to be assessed in a large-scale phase 3 study, CARDIO-TTRansform, which will have data read out in 2025.

The primary result showed a highly significant effect of edaravone dexborneol on good functional outcome, defined by scores of 0 (no symptoms) or 1 (some symptoms) on the standard modified Rankin scale assessed at 90 days postrandomization.

Repetitive transcranial magnetic stimulation, a more widely used symptomatic treatment, was able to improve several outcomes for patients with cerebellar ataxia, especially at high frequencies.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders and hypersomnias.

The study suggests a potential link between poor oral health and changes in brain health, emphasizing the importance of oral care.

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Stephen From. [LISTEN TIME: 22 minutes]

in the study, no association was found between severity of obstructive sleep apnea according to apnea-hypopnea index and functional independence at 3 months following stroke.

After a positive phase 1 study, DNL788, an RIPK1 inhibitor, failed to distinguish itself from placebo in HIMALAYA.

In a cohort of nearly 250 patients with chronic or episodic migraine, less than 2% of patients experienced adverse events while on combination treatment.

The professor in the Department of Translational Neuroscience at Barrow Neurological Institute discussed several topics related to ALS research and the emerging biomarkers in recent years ahead of the 2024 MDA Clinical and Scientific Conference.

Stephen Samples, MD, provided perspective as the newly appointed chair of neurology at Allegheny Health Network, and the responsibilities that come with constructing an effective neurology department.

IVIg and SCIg exhibit differing effects on cytokine profiles in CIDP, potentially due to their distinct pharmacokinetics.

Atogepant demonstrated notable efficacy in reducing monthly migraine days compared with placebo, in addition to maintaining a well-tolerated and safe profile.

In addition the reductions in the number of new gadolinium-enhancing lesions, frexalimab lowered plasma levels of neurofilament light and CXCL13, a biomarker of inflammatory activity.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

Patients with aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder exhibited higher urine pH compared to those with multiple sclerosis and healthy controls.

The efficacy of vamorolone at a dose of 6 mg/kg/d was maintained over 48 weeks of treatment for all 5 motor outcomes.

Considering the favorable safety profile and acknowledging the unmet therapeutic needs in Huntington disease, further investigation of laquinimod or other immune-modulating therapeutics might be warranted.

Omaveloxolone is an oral, once-daily medication indicated for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older in both the United States and the European Union.

After showing inconsistent results in previous trials, AVP-786 did not demonstrate statistically significant outcomes vs placebo on the primary outcome of change in Cohen-Mansfield Agitation Inventory.

TAK-861, an orexin receptor 2 agonist, demonstrated efficacy and safety in a phase 2b trial for narcolepsy type 1.

Topline results from the RESCUE trial indicate that RNS60, an anti-inflammatory agent, demonstrates safety and potential efficacy in acute ischemic stroke.

New findings from the TIMELESS trial suggest that tenecteplase within 4.5 to 24 hours post-stroke might benefit certain subgroups, despite overall neutral outcomes.

Using a cohort of more than 20,000 patients with ischemic stroke, those on AI-CDSS experienced less vascular events of hemorrhagic stroke, myocardial infarction, or vascular death.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders, and specifically, Duchenne muscular dystrophy.

Tirofiban treatment in acute ischemic stroke reduced early neurological deterioration compared to oral antiplatelet therapy alone, warranting further investigation.